Drug Profile
LY 3009385
Alternative Names: LY3009385Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Singapore (SC, Injection)
- 13 Apr 2012 Eli Lilly completes a phase I trial for Type 2 diabetes mellitus (in healthy volunteers) in Singapore (NCT01477567)
- 16 Mar 2012 Eli Lilly completes enrolment in its phase I trial for Type 2 diabetes mellitus (in healthy volunteers) in Singapore (NCT01477567)